Ser399
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser399  -  PAR1 (human)

Site Information
sDPSsyNssGQLMAs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3627502

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 )
Disease tissue studied:
breast cancer ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on PAR1:
receptor desensitization, altered ( 3 )

References 

1

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

2

Zhou J (2011) CST Curation Set: 12497; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Hammes SR, Shapiro MJ, Coughlin SR (1999) Shutoff and agonist-triggered internalization of protease-activated receptor 1 can be separated by mutation of putative phosphorylation sites in the cytoplasmic tail. Biochemistry 38, 9308-16
10413505   Curated Info